Snowball logo
logo
GENT

Gentian Diagnostics AS

GENT OL
NOK 39.00-NOK 0.30  (0.76%)
Estimate
EPS
-0.55
Beta
0.454
Growth
Revenue, YoY
14.23%
Net income, YoY
325.22%
FCF, YoY
-116.78%
Forecast
P/E (FWD)
15.1
EPS (FWD)
2.58
Dividends
Dividend yield
1.54%
Annual payout
NOK 0.60
Next ex. div date
May 6, 27
Payout
46.54%
Dividend growth streak
1 year
Div.rating
About the company
Ticker
GENT
ISIN
NO0010748866
Country
Norway
Sector (GICS)
Healthcare
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.

Frequently asked questions

What sector does Gentian Diagnostics AS (GENT) operate in?

Gentian Diagnostics AS belongs to the Healthcare sector and operates in the Medical Devices industry.

What is Gentian Diagnostics AS (GENT) current stock price?

As of the latest data, Gentian Diagnostics AS stock price is NOK 39.00, with a previous close of NOK 39.30. Gentian Diagnostics AS lost -NOK 0.30 in the last trading session, representing a -0.76% loss.

What is Gentian Diagnostics AS (GENT) current market capitalization?

Gentian Diagnostics AS market cap is approximately 602.89 million.

What is Gentian Diagnostics AS (GENT) Earnings Per Share (EPS)?

The trailing EPS is -NOK 0.55, and the forward EPS is NOK 2.58.

Does Gentian Diagnostics AS (GENT) pay dividends?

Yes. Gentian Diagnostics AS pays annual dividends with an annualized yield of 1.54% and an estimated annual payout of NOK 0.60 per share.

When is the next ex-dividend date for Gentian Diagnostics AS (GENT)?

The next ex-dividend date is scheduled for May 06, 2027.

What is Gentian Diagnostics AS (GENT) beta (volatility) score?

Gentian Diagnostics AS has a beta of 0.454, indicating lower volatility than the overall market.